Psoriasis (PsO) patients at higher risk for serious liver disease
November 2, 2017
Being Overweight Increases Cancer Risk, Two New Studies Show
November 3, 2017
Show all

MS Progression Halted Over Five Years by Lemtrada, Study Reports

Lemtrada research continues to back this MS medication.

Two short courses of Lemtrada (alemtuzumab) prevented multiple sclerosis from becoming active and progressing for five years, a study reported.

Lemtrada’s maker, Sanofi-Genzyme, said the study covered the two-year CARE-MS II Phase 3 clinical trial (NCT00548405) and a long-term extension (NCT00930553) trial of people with relapsing-remitting MS.

In addition to demonstrating Lemtrada’s effectiveness, the study showed that it was safe, researchers said.

Read full article: MS Progression Halted Over Five Years by Lemtrada, Study Reports

Read Full Article: MS Progression Halted Over Five Years by Lemtrada, Study Reports 

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.